Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 111Neoplasms 22Neoplasm Metastasis 17Brain Neoplasms 15Breast Neoplasms, Male 13Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Glioblastoma 5Colorectal Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 4Carcinoma, Ovarian Epithelial 4Salivary Gland Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Ependymoma 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumors 2Recurrence 2Osteitis Deformans 2Oligodendroglioma 2Neuroma, Acoustic 2Neurofibromatosis 2 2Gallbladder Neoplasms 2Esophageal Neoplasms 2

Interventions

Trastuzumab 3pyrotinib 1pertuzumab 1copanlisib 1Vinorelbine 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER2 Positive Breast Cancer × Lapatinib × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡